Intellia Therapeutics, Inc. NTLA
Caution (early) Health Tech sector · Intellia — CRISPR gene-editing therapies, still clinical-stage and pre-revenue.
Intellia Therapeutics, Inc. (NTLA) is an early-stage Health Tech company, graded Caution (early) on FrontierLab's evidence-based quality rubric (data as of 2026-10-05). Revenue grew 12.6% year-over-year at a -46.5% gross margin. Gross-profits-to-assets is -0.03; Rule of 40 is -699.1. Net share issuance 28.7% YoY (heavy issuance). 4 risk flags are noted below. Analyst mix: 14 buy / 7 hold / 3 sell. Track record: 27% of Early-stage-graded names beat the S&P over 63 sessions (95% CI 15–44%, N=33). Median excess vs the S&P was -14.6%.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | 12.6% |
|---|---|
| Gross margin | -46.5% |
| Gross profits / assets | -0.03 |
| Rule of 40 | -699.1 |
| Net margin | -711.7% |
| Cash runway (months) | 11.3 |
| PEG | — |
| Price / sales | 28.8 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ~ Revenue growth — 12.6% (pass ≥ 20%)
- ✗ Capital efficiency
- ✗ Gross margin — -46.5% (pass ≥ 60% · Health Tech)
- ✓ Gross-margin trend — 433.5 (pass ≥ 2)
- ~ Share dilution — 28.7%
- ✗ Competitive moat — None
- ✓ Market size (TAM) — Large
Grade history
- 2026-06-17 — Caution (early) (from Weak (early))
- 2026-06-10 — Weak (early) (first graded)
Every grade change since FrontierLab began tracking this name — the receipts behind the current grade.
How have Early-stage-graded names performed?
The forward returns of all Early-stage-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 45% of Early-stage-graded names beat the S&P over 21 sessions (95% CI 29–62%, N=31). | Median excess vs the S&P was -3.2%. |
| ~3 months | 27% of Early-stage-graded names beat the S&P over 63 sessions (95% CI 15–44%, N=33). | Median excess vs the S&P was -14.6%. |
| ~6 months | building — 46 more sessions needed | |
How have this name's flags scored?
| Flag | N | Mean excess vs S&P |
|---|---|---|
| Burning cash — operating margin is negative. | 36 | -6.5% |
| Cash runway ~11 months at current burn — a raise (and dilution) looks likely. | sample still too small to report (need ≥ 8) | |
| Thin gross margin — keeps little of each sales dollar (judge it against its industry). | 21 | -18.4% |
| Heavy dilution (~29%/yr) — top-decile share issuers have historically underperformed. | sample still too small to report (need ≥ 8) | |
These per-flag figures are observational — a flag firing is not a randomized assignment, so any edge can reflect what kind of names trip a flag, not the flag itself. Descriptive, not causal.
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
How it compares
Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.
Fundamentals
| Market cap | $1.71B |
|---|---|
| Stage | Early |
| Share issuance (YoY) | 28.7% · heavy issuance |
| Moat | None |
| TAM | LARGE |
| P/E (trailing) | — |
| EPS (trailing) | $-3.36 |
| Burn multiple | 7.8 |
| Gross-margin trend (pts) | 433.5 |
| Cash / assets | 0.51 |
| Accruals (%) | 7.3% |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — describes the past, not a signal
Low reached Nov 20, 2025 · high reached Oct 20, 2025 — by daily close.
| Price | $12.26 (as of 2026-10-02) |
|---|---|
| Last session move | — |
| % off 52-wk high | -56.6% |
| RSI (14) | 51 |
| Relative volume | 1× |
Risk flags
Insider activity (90 days)
| Cluster buyers | 0 |
|---|---|
| Sellers | 2 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 4 |
|---|---|
| Buy | 10 |
| Hold | 7 |
| Sell | 2 |
| Strong sell | 1 |
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
From the headlines
Temporary weakness viewed as buying opportunity; clinical progress focus.
AI take — daily, AI-generated
AI leans cautious
Negative gross margin (-46.5%) and minimal runway (11.3 months) are red flags that dwarf the clinical optimism; this is a pre-revenue or early-stage biotech with execution risk, not a near-term growth story.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Health Tech names
← All Health Tech names · Open NTLA in the interactive screener →
Data as of 2026-10-05 08:19 (end-of-day). How grades are computed →